Source: The Journal of Infectious Diseases. Unidade: FMRP
Subjects: ADENOVIRIDAE, CHIMPANZÉS, IMUNOGENICIDADE DA VACINA, CRIANÇAS, DOENÇAS RESPIRATÓRIAS, VACINAS
ABNT
SÁEZ-LLORENS, Xavier et al. Safety and immunogenicity of a ChAd155-vectored respiratory syncytial virus vaccine in infants 6–7 months of age: a phase 1/2 randomized trial. The Journal of Infectious Diseases, 2024Tradução . . Disponível em: https://doi.org/10.1093/infdis/jiad271. Acesso em: 30 ago. 2024.APA
Sáez-Llorens, X., Norero, X., Mussi-Pinhata, M. M., Luciani, K., de la Cueva, I. S., Díez-Domingo, J., et al. (2024). Safety and immunogenicity of a ChAd155-vectored respiratory syncytial virus vaccine in infants 6–7 months of age: a phase 1/2 randomized trial. The Journal of Infectious Diseases. doi:10.1093/infdis/jiad271NLM
Sáez-Llorens X, Norero X, Mussi-Pinhata MM, Luciani K, de la Cueva IS, Díez-Domingo J, Lopez-Medina E, Epalza C, Brzostek J, Szymański H, Boucher FD, Cetin BS, De Leon T, Dinleyici EC, Gabriel MÁM, Ince T, Macias-Parra M, Langley JM, Martinón-Torres F, Rämet M, Kuchar E, Pinto J, Puthanakit T, Baquero-Artigao F, Gattinara GC, Arribas JMM, Amador JTR, Szenborn L, Tapiero B, Anderson EJ, Campbell JD, Faust SN, Nikic V, Zhou Y, Pu W, Friel D, Dieussaert I, Lopez AG, McPhee R, Stoszek SK, Vanhoutte N. Safety and immunogenicity of a ChAd155-vectored respiratory syncytial virus vaccine in infants 6–7 months of age: a phase 1/2 randomized trial [Internet]. The Journal of Infectious Diseases. 2024 ;[citado 2024 ago. 30 ] Available from: https://doi.org/10.1093/infdis/jiad271Vancouver
Sáez-Llorens X, Norero X, Mussi-Pinhata MM, Luciani K, de la Cueva IS, Díez-Domingo J, Lopez-Medina E, Epalza C, Brzostek J, Szymański H, Boucher FD, Cetin BS, De Leon T, Dinleyici EC, Gabriel MÁM, Ince T, Macias-Parra M, Langley JM, Martinón-Torres F, Rämet M, Kuchar E, Pinto J, Puthanakit T, Baquero-Artigao F, Gattinara GC, Arribas JMM, Amador JTR, Szenborn L, Tapiero B, Anderson EJ, Campbell JD, Faust SN, Nikic V, Zhou Y, Pu W, Friel D, Dieussaert I, Lopez AG, McPhee R, Stoszek SK, Vanhoutte N. Safety and immunogenicity of a ChAd155-vectored respiratory syncytial virus vaccine in infants 6–7 months of age: a phase 1/2 randomized trial [Internet]. The Journal of Infectious Diseases. 2024 ;[citado 2024 ago. 30 ] Available from: https://doi.org/10.1093/infdis/jiad271